Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 September 2005, Vol. 106, No. 6, pp. 2206-2214.
Prepublished online as a Blood First Edition Paper on June 7, 2005; DOI 10.1182/blood-2005-01-0062.


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-01-0062v1
106/6/2206    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Banovic, T.
Right arrow Articles by Hill, G. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Banovic, T.
Right arrow Articles by Hill, G. R
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted January 7, 2005
Accepted May 5, 2005

TGF{beta} in allogeneic stem cell transplantation: Friend or foe?

Tatjana Banovic, Kelli P MacDonald, Edward S Morris, Vanessa Rowe, Rachel Kuns, Alistair Don, Jane Kelly, Steven Ledbetter, Andrew D Clouston, and Geoffrey R Hill*

The Queensland Institute of Medical Research, Brisbane, QLD, Australia
The Queensland Institute of Medical Research, Brisbane, QLD, Australia; Department of Stem Cell Transplantation, Royal Brisbane Hospital, Brisbane, QLD, Australia
Genzyme Corporation, Framingham, MA, USA
Department of Pathology, University of Queensland, Brisbane, QLD, Australia

* Corresponding author; email: Geoff.Hill{at}qimr.edu.ai.

Donor treatment with G-CSF attenuates the ability of donor T cells to induce acute GVHD (aGVHD) but increases the severity of chronic GVHD (cGVHD). We investigated the role of the regulatory cytokine TGF{beta} in this paradox in well established murine models of acute and chronic GVHD where recipients are transplanted with splenocytes from donors treated with G-CSF. Neutralization of TGF{beta} after stem cell transplantation (SCT) significantly increased aGVHD and the concurrent prevention of IL-10 production further exaggerated this effect. Early following SCT, donor T cells were the predominant source of TGF{beta} and were able to attenuate aGVHD in a TGF{beta}-dependant fashion. Whilst the neutralization of TGF{beta} augmented the proliferation and expansion of donor T cells after SCT, it paradoxically impaired cellular cytotoxicity to host antigens and associated graft-versus-leukemia (GVL) effects. In cGVHD, neutralization of TGF{beta} from day 14 after SCT attenuated histopathology and CD11b+ mononuclear cells infiltrating sclerodermatous skin produced 50-fold more TGF{beta} than corresponding T cells. Thus, while the production of TGF{beta} by donor T cells early after transplantation attenuates aGVHD and is required for optimal GVL, the production of TGF{beta} late after SCT is preferentially from mononuclear cells and mediates cGVHD. These data have important implications for the timing of therapeutic TGF{beta} neutralization to prevent cGVHD after allogeneic SCT.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
N. Matsuno, A. Wake, N. Uchida, K. Ishiwata, H. Araoka, S. Takagi, M. Tsuji, H. Yamamoto, D. Kato, Y. Matsuhashi, et al.
Impact of HLA disparity in the graft-versus-host direction on engraftment in adult patients receiving reduced-intensity cord blood transplantation
Blood, August 20, 2009; 114(8): 1689 - 1695.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Banovic, K. A. Markey, R. D. Kuns, S. D. Olver, N. C. Raffelt, A. L. Don, M. A. Degli-Esposti, C. R. Engwerda, K. P. A. MacDonald, and G. R. Hill
Graft-versus-Host Disease Prevents the Maturation of Plasmacytoid Dendritic Cells
J. Immunol., January 15, 2009; 182(2): 912 - 920.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Kanter, S. Y. Khan, M. Kelher, L. Gore, and C. C. Silliman
Oncogenic and Angiogenic Growth Factors Accumulate during Routine Storage of Apheresis Platelet Concentrates
Clin. Cancer Res., June 15, 2008; 14(12): 3942 - 3947.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Fujii, G. Cuvelier, K. She, S. Aslanian, H. Shimizu, A. Kariminia, M. Krailo, Z. Chen, R. McMaster, A. Bergman, et al.
Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group
Blood, March 15, 2008; 111(6): 3276 - 3285.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. P. A. MacDonald, R. D. Kuns, V. Rowe, E. S. Morris, T. Banovic, H. Bofinger, B. O'Sullivan, K. A. Markey, A. L. Don, R. Thomas, et al.
Effector and regulatory T-cell function is differentially regulated by RelB within antigen-presenting cells during GVHD
Blood, June 1, 2007; 109(11): 5049 - 5057.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Sakoda, D. Hashimoto, S. Asakura, K. Takeuchi, M. Harada, M. Tanimoto, and T. Teshima
Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease
Blood, February 15, 2007; 109(4): 1756 - 1764.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
V. Rowe, T. Banovic, K. P. MacDonald, R. Kuns, A. L. Don, E. S. Morris, A. C. Burman, H. M. Bofinger, A. D. Clouston, and G. R. Hill
Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation
Blood, October 1, 2006; 108(7): 2485 - 2492.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. S. Morris, K. P. A. MacDonald, and G. R. Hill
Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?
Blood, May 1, 2006; 107(9): 3430 - 3435.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Rutella, F. Zavala, S. Danese, H. Kared, and G. Leone
Granulocyte Colony-Stimulating Factor: A Novel Mediator of T Cell Tolerance
J. Immunol., December 1, 2005; 175(11): 7085 - 7091.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020